Physicians are unequivocal about who is the big kahuna in the vaccine industry. Asked to rank vaccine manufacturers on five metrics, physicians produced a leaderboard that reads Pfizer, yawning gap, Merck.ZoomRx generated the ranking by asking 50 physicians to name the top vaccine manufacturers in five areas: reputation, innovation, patient centricity, promotions and HCP centricity.

医生们明确表示谁是疫苗行业的大人物。医生们被要求根据五个指标对疫苗制造商进行排名，他们制作了一个排行榜，上面写着辉瑞、哈宁盖普、默克。ZoomRx通过要求50名医生在五个领域列出顶级疫苗制造商的名字来获得排名：声誉、创新、以患者为中心、促销和HCP为中心。

The doctors ranked 13 vaccine manufacturers, but the same name kept appearing toward the top of their lists, regardless of the metric being assessed. Around 80% of respondents ranked Pfizer as one of the top three companies in every category. Merck came closest to keeping pace with Pfizer but was still a long way back.

医生们对13家疫苗制造商进行了排名，但不管评估的指标是什么，同一个名字一直排在他们名单的首位。大约80%的受访者将辉瑞列为各个类别中排名前三的公司之一。默克（Merck）最接近辉瑞（Pfizer），但仍有很长的路要走。

The closest Merck got to Pfizer was in the innovation and patient centricity categories, where the front-runner had a 23 percentage point lead over second place. “Pfizer leads by a huge margin across all metrics,” ZoomRx wrote in its assessment of the results. “Their quick response to the pandemic with the COVID-19 vaccine is still holding high regards and recognition.”RelatedAbbVie tops, J&J drops as physicians rank immunology players As ZoomRx noted, Pfizer’s vaccine team followed up its pandemic success with three launches last year.

默克（Merck）与辉瑞（Pfizer）最接近的领域是创新和以患者为中心，领先者领先第二名23个百分点。ZoomRx在对结果的评估中写道：“辉瑞在所有指标上都以巨大的优势领先。”。“他们对新型冠状病毒肺炎疫苗的快速反应仍然受到高度重视和认可。”相关Abbvie tops，J＆J下降，正如ZoomRx所指出的那样，随着医生对免疫学参与者的排名，辉瑞公司的疫苗团队继其大流行成功后，于去年推出了三次。

The Big Pharma entered the nascent respiratory syncytial virus (RSV) space with Abrysvo, added Prevnar 20 to its successful pneumococcal franchise and broke new ground with its meningitis vaccine Penbraya. Pfizer’s CEO bemoaned the “bad launch” of Abrysvo, but sales still hit $515 million in the fourth quarter.Pfizer’s rivals for the COVID-19, RSV and pneumococcal markets feature in the chasing pack.

这家大型制药公司与Abrysvo一起进入了新生的呼吸道合胞病毒（RSV）领域，在其成功的肺炎球菌特许经营中加入了Prevnar 20，并用脑膜炎疫苗Penbraya开创了新局面。辉瑞首席执行官对Abrysvo的“糟糕发布”表示遗憾，但第四季度销售额仍达到5.15亿美元。辉瑞公司在新型冠状病毒、呼吸道合胞病毒和肺炎球菌市场上的竞争对手也在追逐中。

Merck came in second on four of the five metrics, only slipping to third place behind Moderna on the reputation rank. Moderna and GSK fought for t.

默克（Merck）在五项指标中的四项中排名第二，在声誉排名上仅落后于摩德纳（Moderna）。摩德纳和葛兰素史克为t。